Late last year, EssilorLuxottica announced that the U.S. Food and Drug Administration (FDA) granted market authorization for its Essilor® Stellest® lens through the De Novo pathway. Notably, the FDA had already recognized this innovation as a Breakthrough Technology in 2021. As a result, the Essilor® Stellest® lens has become the first and only spectacle lens in the United States authorized to slow myopia progression in children. Clinical studies further demonstrate its effectiveness, showing an average 71% reduction in myopia progression over two years.
Rising Myopia Burden in India
Meanwhile, myopia is emerging as a major public health concern in India. Experts project that nearly 50% of urban children could be affected by 2050. In response, EssilorLuxottica aims to strengthen myopia care in India by introducing FDA-authorized innovations aligned with National Accreditation Board for Hospitals & Healthcare Providers standards and global best practices. By equipping doctors, parents, and institutions with evidence-based solutions, the company seeks to improve early intervention and long-term outcomes.
Bridging the Gap in Early Detection
However, a significant challenge persists. Since routine eye testing is not mandatory in India, many children remain undiagnosed or untreated. Therefore, parents must prioritize regular eye check-ups, especially during back-to-school preparations. Importantly, myopia is not merely a refractive error—it is a progressive condition. While standard lenses correct vision, they do not slow disease progression. Consequently, timely and annual screenings are essential to ensure both clear vision and effective management.
Strategic Expansion Across India
To address this growing need, EssilorLuxottica is focusing on regions with high awareness and early adoption potential. Initially, the company is targeting metro cities and emerging hubs such as Pune, Coimbatore, Ahmedabad, Kochi, and Chandigarh. Subsequently, it plans to expand into Tier-2 and Tier-3 cities through collaborations with ophthalmologists, optometrists, and optical networks. In parallel, professional education programs will support the adoption of advanced myopia management practices.
Expert Perspectives on the Breakthrough
As per the press release, highlighting the significance of this approval, Dr. Kunal Srivastava, Director of Medical & Professional Affairs at EssilorLuxottica India, emphasized that FDA authorization represents a global benchmark for clinical credibility. He noted that this innovation transforms traditional corrective lenses into a medical solution, marking a pivotal shift in how eyecare professionals approach myopia.
Similarly, Venu Ambati, President of EssilorLuxottica India, described the development as a major milestone. He stressed that early intervention is critical, as delaying treatment can lead to lifelong vision complications. According to him, Essilor® Stellest® not only addresses an urgent parental need but also empowers families to take proactive control of their children’s eye health.
Backed by Decades of Research
Over the past four decades, EssilorLuxottica has led extensive research in myopia management. This sustained effort culminated in the global launch of the Essilor® Stellest® lens, which is now used by millions of children worldwide. By combining scientific innovation with clinical evidence, the company continues to provide reliable solutions that improve both immediate vision and long-term eye health.
Addressing a Global Epidemic
Ultimately, myopia is not just a local concern—it is a global epidemic. By 2050, experts estimate that half of the world’s population could be affected, including nearly 740 million children. Furthermore, high myopia significantly increases the risk of serious eye conditions later in life. Therefore, the focus must shift from simple correction to proactive control. Innovations like Essilor® Stellest® represent a crucial step forward in safeguarding the visual health of future generations.